Clinical trials: Exudative Macular Degeneration
Ophthalmopathy, Wet Macular Degeneration
Reading Speed Improvements in Wet-AMD Patients After Ranibizumab Treatment
AMD (age-related macular degeneration), is the leading cause of blindness in individuals over the age of 55. There is no cure for wet-AMD but anti-VEGF treatments significantly minimize the vision loss over time.
- Trial name
- PAMER (NCT04982484)
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Régional Metz-Thionville
Exudative Macular Degeneration
Treatment of Neovascular AMD: Artificial Intelligence in Real-world Setting
The purpose of this study is to implement quantitative assessment tools for the treatment of active neovascular AMD patients in a real-world setting in order to provide advantages for both patients (treatment burden) and…
- Trial name
- NCT05093374
- Testing
- anti-VEGF agent
- Where
- Austria
- Volunteers
- 290 people
- Sponsor
- Medical University of Vienna
Macular Degeneration
Intravitreal Bevacizumab Combined With PDT Versus Bevacizumab to Treat Exudative AMD
The purpose of this study is to determine the association of bevacizumab and PDT is safety and effective in the treatment of exudative AMD
- Trial name
- NCT00684853
- Testing
- bevacizumab, vetaporfin
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Federal University of São Paulo
Wet Macular Degeneration
Sub-tenon Triamcinolone Acetonide in Age-Related Macular Degeneration as Adjunct to Ranibizumab
In the Western World, Age Related Macular Degeneration (ARMD) is a leading cause of blindness. This disease was once thought to be a natural part of aging, but recent research has introduced effective treatments.
- Trial name
- STAR (NCT01249937)
- Testing
- Ranibizumab, Triamcinolone Acetonide
- Where
- Canada
- Volunteers
- 30 people
- Sponsor
- University Health Network, Toronto
Macular Degeneration, Maculopathy, Age-Related
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
The purpose of this study is to demonstrate that anecortave acetate is superior to placebo in maintenance of visual acuity at the 12- and 24-month visits.
- Trial name
- NCT00058994
- Testing
- anecortave acetate
- Where
- United States
- Sponsor
- Alcon Research
Neovascular Age-related Macular Degeneration
Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related…
- Trial name
- DRAGON (NCT01775124)
- Testing
- Ranibizumab
- Where
- 23 sites in China
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration (AMD)
EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).
This prospective, observational, open-label study evaluates early treatment response to intravitreal aflibercept 8 mg in patients with exudative age-related macular degeneration.
- Trial name
- ELEV8 (NCT07434713)
- Testing
- treatment with Aflibercept 8mg (Eylea)
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Macular Degeneration, Wet, Metamorphopsia
M Charts Versus Amsler Test in Evaluating Metamorphopsia in nAMD
Age-related macular degeneration (AMD) is a complex eye disorder and the most common macular disease affecting millions of aged people in the developed countries, with an estimation that the number of AMD patients will be…
- Trial name
- MVAinAMD2022 (NCT05324150)
- Where
- Italy
- Volunteers
- 57 people
- Sponsor
- Ospedale Santa Croce-Carle Cuneo
Age-Related Macular Degeneration
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
The purpose of the study is to evaluate the safety, tolerability, immunogenicity, and bioactivity of a single intravitreal (IVT) administration of DE-122 in subjects with refractory exudative age-related macular degeneration…
- Trial name
- PAVE (NCT02555306)
- Testing
- 0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122
- Where
- 5 sites in United States
- Volunteers
- 12 people
- Sponsor
- Santen Inc.
Macular Degeneration Exudative Eye Left, Macular Degeneration Exudative Eye Right
OCTA (Optical Coherence Angiography Tomography) Versus Structural OCT(Optical Coherence Tomography) in Neovascular AMD (Age Macular Degeneration)
The objective is to find if there is a relationship between the Fractal Dimension, the gap, vascular density (VD), the surface, the span ratio and the status of the choroidal neovessels to adjust the interval between 2…
- Trial name
- QUAOBARE (NCT03939195)
- Testing
- Follow-up
- Where
- 3 sites in France
- Volunteers
- 130 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
Wet Macular Degeneration, Cataract Extraction
Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery
To-date there have been only very few studies to examine the effect of cataract surgery to patients with wet age-related macular degeneration.
- Trial name
- NCT03944070
- Testing
- Ranibizumab
- Where
- Greece
- Volunteers
- 16 people
- Sponsor
- Ophthalmica Eye Institute
Age-Related Macular Degeneration (AMD), Macular Degeneration
X-82 to Treat Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.
- Conditions
- Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD
- Trial name
- NCT02348359
- Testing
- X-82, Anti-VEGF
- Where
- 35 sites in United States
- Volunteers
- 157 people
- Sponsor
- Tyrogenex
Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema
Cool vs Room-temperature Artificial Tears
Background and Objective: To evaluate the efficacy of cooled versus room temperature artificial tears in reducing post intravitreal injection (IVI) ocular discomfort.
- Conditions
- Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema
- Trial name
- NCT05832996
- Testing
- Refresh Plus Preservative-free Lubricant Eye Drops
- Where
- United States
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Exudative Age-related Macular Degeneration
Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD
The purpose of the study is to determine the safety and efficacy of 4 monthly injections of iSONEP given alone or in combination with Lucentis, Avastin or Eylea in subjects with wet Age-related Macular Degeneration (AMD).
- Trial name
- Nexus (NCT01414153)
- Testing
- 4.0 mg iSONEP, 0.5 mg iSONEP, 0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea
- Where
- 44 sites in United States
- Volunteers
- 158 people
- Sponsor
- Lpath, Inc.
Wet Macular Degeneration
The Impact of Baseline Visual Acuity on the Treatment Outcomes in Patients Treated With AflIbercept in Real-life Clinical Setting
The study will assess the mean change in Visual Acuity (VA) (overall and stratified by baseline VA) at year 1 and 2 of treatment with Aflibercept in real-life setting.
- Trial name
- INSIGHT (NCT03278262)
- Testing
- Aflibercept (Eylea, BAY86-5321)
- Where
- Sweden
- Volunteers
- 2,312 people
- Sponsor
- Bayer
Age-Related Maculopathy
Safety and Effectiveness Investigation for Dry, Non-Exudative Age Related Macular Degeneration (AMD) Using Rheopheresis
SUMMARY Age-related macular degeneration (AMD) is the leading cause of late onset visual impairment and legal blindness in people 65 years of age or older in the United States.
- Trial name
- RHEO-AMD (NCT00460967)
- Testing
- Rheopheresis
- Where
- 39 sites in United States, Canada and 1 more
- Volunteers
- 325 people
- Sponsor
- OccuLogix
Macular Degeneration
Pegaptanib Sodium on Foveal Thickening in Patients With Exudative Subfoveal Age-Related Macular Degeneration (AMD)
The purpose of this study is to determine if Macugen™ reduces foveal thickness and improves vision in patients with wet AMD.
- Trial name
- NCT00087763
- Testing
- Macugen ™ (pegaptanib sodium injection)
- Volunteers
- 135 people
- Sponsor
- Eyetech Pharmaceuticals
Age-related Macular Degeneration
Pilot Study of Lucentis Combined With Proton Beam Irradiation in Treating Wet Age-related Macular Degeneration
Because a possible synergism of radiation and inhibitors of vascular endothelial growth factor has been shown in cancer patients and patients with wet macular degeneration, this pilot study is being conducted to determine whether…
- Trial name
- NCT00517010
- Testing
- Proton beam irradiation and ranibizumab
- Volunteers
- 6 people
- Sponsor
- University of California, Davis
Age Related Macular Degeneration
RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
This study is a single-center, open label, 4-month study, designed to evaluate the safety and treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to previously untreated neovascular AMD.
- Trial name
- TEMPURA (NCT04895293)
- Testing
- RBM-007 Injectable Solution
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Maturi, Raj K., M.D., P.C.
Neovascular Age-related Macular Degeneration, Wet Macular Degeneration
Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy
This is a prospective, observational study designed to evaluate the long-term safety and efficacy of RGX-314. Eligible participants are those who were previously enrolled in a clinical study in which they received a single…
- Trial name
- RGX-314 SRLTFU (NCT03999801)
- Testing
- RGX-314
- Where
- 9 sites in United States
- Volunteers
- 865 people
- Sponsor
- AbbVie